Unity Biotechnology, INC 8-K filings

Unity Biotechnology, Inc. has filed for dissolution and finalized the early termination of its primary office and laboratory lease, incurring significant costs and contingent liabilities.

Unity Biotechnology, Inc. stockholders approved the company's liquidation and dissolution at a special meeting held on September 18, 2025.

Unity Biotechnology, Inc. filed an amendment to its current report, primarily to include a former address, while reiterating its plan for dissolution and the strategic issuance of a Series A Preferred Stock to facilitate the stockholder vote on the wind-down.

Unity Biotechnology, Inc. has issued a Series A Preferred Share to its sole director, granting significant voting power to align with common stockholder votes on a proposed company dissolution.

UNITY Biotechnology, Inc. has received notification of delisting from Nasdaq due to its status as a public shell with no operating business, leading the company to approve a plan for complete liquidation and dissolution.

Unity Biotechnology, Inc. has received notices from Nasdaq regarding non-compliance with minimum bid price and stockholders' equity requirements, potentially leading to delisting if not resolved by specified deadlines.

UNITY Biotechnology is reducing its workforce and exploring strategic alternatives after announcing full 36-week results from its Phase 2b ASPIRE clinical trial for UBX1325 in diabetic macular edema.

Unity Biotechnology announced Q1 2025 financial results and provided an update on its ASPIRE study in diabetic macular edema (DME), showing vision improvements comparable to aflibercept but failing to meet the primary endpoint.

Paul L. Berns resigned from Unity Biotechnology's Board of Directors, effective April 4, 2025.

UNITY Biotechnology's UBX1325 shows promising vision gains in diabetic macular edema patients, comparable to aflibercept, in Phase 2b ASPIRE study.

Unity Biotechnology received a notification from Nasdaq on March 14, 2025, indicating that it no longer meets the minimum stockholders' equity requirement for continued listing.

Unity Biotechnology appoints Dr. Yehia Hashad, a seasoned ophthalmologist and executive from Bausch + Lomb, to its Board of Directors and Science Committee to leverage his expertise in retinal diseases and drug development.

Unity Biotechnology announces its Q4 and full year 2024 financial results, highlighting progress with UBX1325 in diabetic macular edema (DME) and providing updates on its cash runway.

Unity Biotechnology has appointed Dr. Federico Grossi, former chief medical officer of Apellis Pharmaceuticals, as its new Chief Medical Officer, effective January 1, 2025.

Unity Biotechnology announced its third quarter 2024 financial results, highlighting progress in its UBX1325 clinical trial for diabetic macular edema and providing an update on its cash runway.

Unity Biotechnology announced its Q2 2024 financial results, highlighting progress in its ASPIRE clinical trial and a significant reduction in net loss compared to the previous year.

Unity Biotechnology held its annual meeting on June 21, 2024, where stockholders voted on director elections, auditor ratification, and executive compensation.

Unity Biotechnology announced its first quarter 2024 financial results, highlighting progress in its Phase 2b ASPIRE study for diabetic macular edema and providing updates on its cash runway.

Unity Biotechnology announced its full year 2023 financial results, highlighting a reduced net loss and an upsized Phase 2b ASPIRE study for their lead drug candidate, UBX1325.

Unity Biotechnology has identified an error in the classification of warrants issued in 2022, requiring a restatement of financial statements for multiple periods.